***COVID-19 Funding Opportunities* Last Updated: November 13, 2020**

*Below is a running list of Funding Opportunities directly related to COVID-19 that are relevant to School of Medicine Researchers. If you are aware of RFAs that should be listed here, please email Trisha Dant at* *dant@med.unc.edu**. Those shaded in Gray have expired.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Title** | **Deadline** | **Funding Information** | **Purpose and other Notes** |
| Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required) [RFA-TR-20-003](https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html#_3._Additional_Information) | Applications will be accepted on a **rolling basis.** | The budget is limited to $3,000,000 direct costs/year. The project period may be up to three years. | To repurpose existing therapeutic agents to treat COVID-19 sequelae and associated complications that result from SARS-CoV02 infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial. |
| Fast Grants for COVID-19 ([linked here](https://www.mercatus.org/emergent-ventures)) | *Deadline not specified.* For more information you can reach them at emergentventures@mercatus.gmu.edu. | Fast Grants range from $10k-$500k. | Emergent Ventures, a fellowship and grant program from the Mercatus Center at George Mason University is providing fast grants for scientists working at academic institutions. Decisions are usually made within 48 hours. |
| NOSI: Development of Biomedical Technologies for COVID-19 ([NOT-EB-20-007](https://grants.nih.gov/grants/guide/notice-files/NOT-EB-20-007.html)) | (Check RFA for applicable date) | N/A | NIGMS will accept applications for competitive revisions to active U24 awards for eligible organizations to rapidly provide pilot or supplementary funds to researchers studying the development of predictive models for the spread of SARS-CoV-2 and outcomes of possible COVID-19 public health interventions measures in order to accelerate such research. |
| Pandemic/COVID-19 Science, Technology and Social Impact from CISCO Research and Open Innovation [RFA-20-04](http://research.cisco.com/research#rfp-202004) | Unspecified | Unspecified | To solve problems ranging from predictive analytics innovative devices for saving lives to technology for devising voting machines. Cisco is interested in a number of areas, including models for the spread and impact of pandemics, simulation techniques, biomedical/nano sensor devices to detect symptoms and agents, drug screening and contact tracing algorithms, computational biology techniques for sequencing and detecting viral evolutions, collaboration techniques for more effective health, and pandemic data science.  |
| Ecology and Evolution of Infectious Diseases (EEID) ([linked here](https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5269)) | **November 18, 2020** | Unspecified | To support research on the ecological, evolutionary, and social drivers that influence the transmission of dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics.  |
| Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) [PAR-20-237](https://grants.nih.gov/grants/guide/pa-files/PAR-20-237.html) | **December 1, 2020** | Application budgets are limited to $500,000 direct costs annually. The maximum period is 5 years. | This FOA encourages applicants to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups. |
| Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional) [PAR-20-243](https://grants.nih.gov/grants/guide/pa-files/PAR-20-243.html) | **December 2, 2020**, March 2, 2021 | Application budgets are limited to $750,000 direct costs per year. The maximum project period is 3 years.  | To support research to strengthen the healthcare response to COVID-19 and future public health emergencies, and focuses on the role and impact of digital health interventions and wearable devices to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects, particularly in populations who experience health disparities and vulnerable populations.  |
| Mechanistic Studies of the Interaction Between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) [RFA-DK-20-021](https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-021.html) | **December 16, 2020** | NIDDK intends to commit $5,000,000 in FY2021 to fund 11-13 awards. The maximum project period is 3 years. | To support basic and clinical mechanistic research on SARS-CoV-2 and COVID-19 susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. |
| The IBSA Foundation Fellowships: 2020 Call for Research on Coronavirus Infections ([linked here](https://www.ibsafoundation.org/fellowships/fellowship-2020/)) | **December 31, 2020** | Each fellowship is worth € 30,000 | The fellowships are awarded to young researchers under the age of 40 from universities and research institutes around the world who have distinguished themselves for their skills and have ongoing projects of particular relevance in specific areas of research, which includes coronavirus infections this year.  |
| Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States [RFA-IP-21-005](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328584) | The estimated post date is November 4, 2020 with an estimated deadline of **January 8, 2021**. | Approximately 7 awards should be funded with awards ranging between $1,440,000 - $2,150,000. | ***This is a Forecasted Opportunity from the CDC.*** The goal of this RFA is to a) support a network of US institutions that can obtain reliable vaccination information for a population, or cohort of individuals; b) provide accurate estimates of the effectiveness of vaccines against respiratory viruses including influenza, SARS-CoV-2 and other respiratory viruses that may emerge; and c) prevent medically attended influenza-associated illness in the population for whom influenza vaccination is recommended. |
| Notice of Special Interest (NOSI) – Research on Rehabilitation Needs Associated with the COVID-19 Pandemic ([NOT-HD-20-031](https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-031.html)) | The notice applies to due dates on or after **February 5, 2021** through **May 8, 2023**. | N/A | To encourage applications in the following three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:1. Encourage research to address the rehabilitation needs of survivors of COVID-19
2. Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
3. Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
 |
| Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on COVID-19 in Individuals with Down Syndrome for the INCLUDE Project ([NOT-OD-20-129](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-129.html)) | **March 12, 2021**, and July 12, 2021 | N/A | he overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus. |
| Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) ([NOT-TR-21-006](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-21-006.html)) | The notice applies to receipt dates from **October 30, 2020 through** **March 16, 2021**. | N/A | NCATS is interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. |
| Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on COVID-19 and the Behavioral and Social Sciences [NOT-OD-20-097](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html) | Applications will be accepted on a rolling basis through **March 31, 2021** | N/A | This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health. |
| Notice of Special interest: SARS-CoV-2 and COVID-19 [(NOT-AI-20-031)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html) | Applies to receipt dates through **April 5, 2021.** | N/A | NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, and projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics. |
| NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System ([NOT-NS-20-051)](https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-051.html) | Applications will be accepted on a rolling basis **through April 14, 2021** | N/A | In order to rapidly improve our understanding of the neurological consequences of infection of SARS-CoV-2 and of COVID-19, NINDS is encouraging the submission of applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus that are directly related to the [NINDS mission](https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission). |
| Notice of Special Interest (NOSI): Availability of Administrative Supplements and Competitive Revision Supplements on COVID-19 within the Mission of NIAAA [NOT-AA-20-011](https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-011.html) | Applications will be accepted on a rolling basis **through April 15, 2021** | N/A | This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes. |
| Notice of Special Interest Regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on 2019 Novel Coronavirus ([NOT-MH-20-047](https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html)) | Applications will be accepted on a rolling basis through **April 15, 2021.** | N/A | NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. |
| Emergency Awards: Rapid Investigation of SARS-COV-2 and COVID-19 (R21 Clinical Trial Not Allowed) [PAR-20-177](https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html?utm_campaign=+42553048&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=) | Applications will be accepted on a rolling basis. The expiration date is **April 30, 2021**.  | The budget for direct costs for the 2-year project period may not exceed $275,000.  | To provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19. NIAID is issuing this FOA in response to the declared public health emergency issues by the HHS Secretary. |
| Emergency Awards: Rapid Investigation of SARS-COV-2 and COVID-19 (R01 Clinical Trial Not allowed)[**PAR-20-178**](https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html?utm_campaign=+42553048&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=) | Applications will be accepted on a rolling basis. The expiration date is **April 30, 2021**. | The total project period ay not exceed 5 years.  | To provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19. NIAID is issuing this FOA in response to the declared public health emergency issues by the HHS Secretary. |
| Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on COVID-19 [NOT-AG-20-022](https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html) | Applications will be accepted on a rolling basis through **May 1, 2021** | N/A | NIA is issuing this NOSI to highlight the urgent need for research on COVID-19. The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.  |
| Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities [NOT-MD-20-019](https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html) | Applications will be accepted on a rolling basis **through May 1, 2021** | N/A | NIMHD is issuing this NOSI to highlight the urgent need for research on the impact of SARS-CoV-2 pandemic causing COVID-19 outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations. |
| Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on COVID-19 ([NOT-ES-20-015](https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html)) | Expiration Date: **May 4, 2021** – check RFA for more information | N/A | NIEHS is particularly interested in applications that will provide insight into the role of the environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. |
| Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations [NOT-MD-20-026](https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-026.html) | Applies to due dates on or after October 5, 2020 and subsequent receipt dates **through May 8, 2021.**  | N/A | To support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations. *One specific area of interest includes studies on the multi-level effects of the COVID-19 pandemic and/or their intersection on access to health care services and continuity of care*. |
| Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to SARS-CoV-2 and COVID-19 ([NOT-AI-20-059)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html) | Applications will be accepted on a rolling basis until **July 2, 2021** | N/A | NIAID is allowing the submission of revisions to grants to enhance select efforts to facilitate the Federal research response. Areas of interested are limited to: 1) support of BSL3 facilities engaged in the SARS-CoV-2/COVID-19 response, 2) generation of critical reagents to support the SARS-CoV-2/COVID-19 research response; 3) expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad community, and 4) expansion of clinical trial infrastructure for urgent SARS-CoV-2/COVID-19 clinical trial activities. |
| Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need ([NOT-TR-20-011](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html)) | Expiration Date: **July 10, 2021** – check RFA for more information) | N/A | NCATS is issuing this NOSI to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings. *Contact* *John Buse* *or* *Andrea Carnegie* *with questions or for assistance.* |
| Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2 ([NOT-AI-20-065](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-065.html)) | Applications will be accepted once a month from **through** **September 14, 2021**. See RFA for specific dates | N/A | This NOSI encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate 1) SARS-CoV-2 candidate vaccines, 2) non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19, 3) therapeutic approaches to treat COVID-19 |
| NSF Rapid Proposals [NSF-20-052](https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp?WT.mc_id=USNSF_80) | Please contact relevant program officer, or, rapid-covid19@nsf.gov. | RAPID proposals may be for up to $200K and up to 1 year in duration.  | NSF is accepting proposals to conduct non-medial, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address the global challenge. NSF encourages the community to respond through existing funding opportunities. Researchers are invited to use the RAPID funding mechanism. |
| NOSI regarding the Availability of Administrative Supplements for Tissue Chips Research on COVID-19 ([NOT-TR-20-016](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html)) | On a rolling basis from **through January 25, 2022** | N/A | NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. |
| Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract ([NOT-HD-20-021](https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-021.html)) | This notice applies to due dates through **July 16, 2023**. | N/A | To invite applications proposing research on emerging viral infections that are thought to primarily impact non-reproductive sites, but may also affect the male and/or female reproductive tract. This NOSI is interested in both ZIKA and coronaviruses, and other yet identified viruses which may significantly impact public health. |
| Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders [NOT-DA-20-058](https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-058.html) | This notices applies to due dates on or after October 5, 2020 and through **January 8, 2024**. | N/A | To stimulate research to evaluate the safety and efficacy of telemedicine or remotely provided treatments for Substance Use Disorder (SUD), and to develop tools for remote collection of data in clinical trials of treatments for SUD. |
| Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome / Acute Lung Injury (ARDS/ALI) ([NOT-HL-20-814](https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-814.html)) | This notice applies to due dates on or after October 5, 2020 and subsequent recipient dates through **July 5, 2024** of reissued FOAs**.** | N/A | To support research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) / acute lung injury (ALI). Heterogeneous transmission of SARS-CoV-2 and outcomes of COVID-19 patients as well as the occurrence of e-cigarette or vaping-associated lung injury are further evidence of the need to better understand ARDS heterogeneity. |
| Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 infection ([NOT-DA-20-084)](https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-084.html) | This notice applies to due date from January 7, 2021 – **September 8, 2024** | N/A | To communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. |
| PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Dissemination and Implementation Awards ([linked here](https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-dissemination-implementation-awards)) | On a rolling basis | $500,000 limit (direct and indirect costs) for Dissemination and Implementation Project Award Enhancements – higher amounts may be considered. The enhancement may not increase the project timeline by more than 12 months | PCORI seeks investigator-initiated proposals that addresses the COVID-19 public health crisis and enhancement to currently funded PCORI Dissemination and Implementation awards. Proposed enhancements should boost the existing Dissemination and Implementation project’s overall impact and do so by responding to needs evolving or emerging in the context of the COVID-19 pandemic. Such needs include, but are not limited to, challenges to mental health and well-being of healthcare workers, social support for vulnerable populations experiencing isolation or restrictions in mobility, prevention and treatment of COVID-19, and health system adaptations to compensate for shortages of personnel and supplies. |
| PCORI Funding Opportunity for COVID-19-Related Enhancements for Existing PCORI-Funded Research Projects ([linked here](https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-research-awards)) | On a rolling basis | $500,000 limit (direct and indirect costs) for Dissemination and Implementation Project Award Enhancements – higher amounts will be considered on a case-by-case basis, based on applicant’s justification of the proposed amount. The enhancement may not increase the project timeline by more than 12 months. | PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Enhancements may include: modest additions to existing aims (such as additional outcomes to be collected as they relate to COVID-19), or an adjunct project that has some relationship to the original award, including a new aim (or aims) designed to produce useful knowledge related to COVID-19 and the original award. Simultaneous adaptation of original aims to account for COVID-19 may also be proposed. Taking advantage of natural experiments in health system, state, and provider responses is strongly encouraged. |
| The Gordon and Betty Moore Foundation is Funding Work in Specific Areas of COVID-19 Research (see purpose and notes).  | Please contact Kavita Hall (kavita.kapur@unc.edu), Director of the Office of Corporate and Foundation Relations with questions | Please contact Kavita Hall (kavita.kapur@unc.edu), Director of the Office of Corporate and Foundation Relations with questions | The Gordon and Betty Moore Foundation is funding work in these COVID-19 areas: 1. Data sources - looking to identify or help develop clinical datasets of hospitalized patients with COVID, aggregating data in real-time across health systems nationally (promising examples include the [Society for Critical Care Medicine’s “VIRUS” COVID-19 registry](https://www.sccm.org/Research/Research/Discovery-Research-Network/VIRUS-COVID-19-Registry) or an EHR based registry such as [Surgisphere](https://surgisphere.com/) which purports to have clinical data on 25,000 COVID+ patients across the world).
2. Clinical Models – using robust clinical data sources, modeling groups are eager to predict which patients with COVID are more likely to die (thus helping with triage decisions and utilization).

If you are working in these areas and/or interested in hearing more about the foundation’s interests, please contact Kavita Hall (kavita.kapur@unc.edu), Director of the Office of Corporate and Foundation Relations. |
| Draper Richards Kaplan (DRK) COVID-19 Urgent Response Initiative ([linked here](https://www.drkfoundation.org/covid-19-funding/)) | Unspecified; but hope is to find opportunities in the next 60-90 days to deploy capital through May, June and July. | Although there are not fixed funding terms, it is anticipated that most funding will be unrestricted capital in the $50K-100K range.  | DRK is actively soliciting proposals for quickly deployable fundable solutions that can immediately provide relief for issues created by the current COVID-19 pandemic. DRK is ready to support proposals tackling the most acute and time-critical social problems caused by the pandemic. |
| Notice of Information: Contributing to the COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis [NOT-CA-20-054](https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-054.html) | This option is only for the duration of the COVID-19 crisis. A notice will be published when the present opportunity is no longer in effect.  | N/A | NCI-funded investigators may have novel insights and research proposals of immediate relevance to SARS-CoV-2 and COVID-19. In those cases, but only for the duration of the present crisis, NCI would consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources under specific conditions (please see RFA). Prior approval must be received.  |
| Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus [NOT-HG-20-030](https://grants.nih.gov/grants/guide/notice-files/NOT-HG-20-030.html) | Applications will be accepted on a rolling basis **through May 15, 2020** | N/A | For NHGRI grantees only (including those with current extension of funds or a no cost extension), we encourage the submission of applications for Competitive Revisions to support genomic research on SARS-CoV-2 and COVID-19 disease. Of particular interest are genomic studies utilizing generalized approaches that take advance of human research or model systems to study the consequences of SARS-CoV-2 infection.  |
| Newton Award for Transformative Ideas during the COVID-19 Pandemic (Department of Defense, [BRO-20-NEWTON](https://www.grants.gov/web/grants/view-opportunity.html?oppId=326034)) | **May 15, 2020** | Up to $100,000 will be provided for up to 10 awards.  | Newton Award recipients will produce novel conceptual frameworks or theoretical approaches to addressing outstanding or emerging challenges facing the scientific community. Given the novelty of and circumstances surrounding this one-time Funding Opportunity Announcement (FOA), the objective of this program is to generate proposals that are equally novel and pioneering. Therefore, this FOA should be viewed as an opportunity to propose basic research that falls outside the bounds of traditional proposals. |
| Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement -  Clinical Trial Optional) [PA-20-072](https://grants.nih.gov/grants/guide/pa-files/PA-20-072.html) | **May 29, 2020** | AHRQ expects to make up to $15 million in PCORTF funds available to fund meritorious revision supplements in FY2020. | The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards that were funded under specific PCOR FOAs, that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis.  |
| Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement -  Clinical Trial Optional) [PA-20-070](https://grants.nih.gov/grants/guide/pa-files/PA-20-070.html) | **May 29, 2020** | AHRQ expects to make at least $2.5M available to fund revision supplements in FY2020. Supplement is not to exceed 12 months. | The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards, (except R13s, T32s, F32s), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis.  |
| American Lung Association COVID-19 and Emerging Research Award([linked here](https://www.lung.org/getmedia/9ff5f39f-ca59-44cb-ace1-96f0df4a7687/covid-19-and-emerging-respiratory-viruses-research-rfp-w-award-application-guide.pdf?utm_source=Funding+Opportunities+Newsletter&utm_campaign=aa2bbd2439-EMAIL_CAMPAIGN_2020_04_14_08_58_COPY_01&utm_medium=email&utm_term=0_3c10bdadac-aa2bbd2439-199026908)) | **May 30, 2020** | The award is for $100,000 per year for up to 2 years. The award is intended to support independent investigators with a stellar track record of accomplishment. | The American Lung Association is looking for proposals to advance research against emerging respiratory pathogens like SARS-CoV-2. All research must directly relate to COVID-19 or other viral respiratory threats that may arise in the future. They are interested in clinical, basic, translational, and population health questions – *refer to the RFA for additional details about this*. |
| Call for Innovation via Transform Fund – Enhancing Member Countries Preparedness and Response to COVID-19 Pandemic([linked here](https://www.isdb-engage.org/en/challenge/call-for-innovation-via-transform-fund-2020)) | **June 1, 2020** (seems to be rolling from April 1, 2020) | There are various categories of funding starting from $50,000. | The Transform Fund Call for Innovation 2020 from the Islamic Development Bank will focus entirely on supporting our Member Countries long-term preparedness and response to the COVID-19 pandemic. The Call for Innovation will reward innovative proposals that will benefit local communities focus on: the application of advanced technology, innovative health supply chain management systems, development of low-cost rapid test and screening methods, and capacity building interventions. *This opportunity was found on the Office of Research Development’s website.* |
| Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on COVID-19 ([NOT-DC-20-004](https://grants.nih.gov/grants/guide/notice-files/NOT-DC-20-004.html)) | On a rolling basis through **June 1, 2020** | N/A | NIDCD is issuing this NOSI to highlight the urgent need for research on SARS-CoV-2 and COVID-19 in relation to NIDCD’s scientific mission areas of hearing, balance, taste, smell, voice, speech and language. |
| NOSI: Availability of Urgent Competitive Revision Supplements on COVID-19 Related to HIV Comorbidities, Coinfections, and Complications within NIDDK’s mission ([NOT-DK-20-020](https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-020.html)) | **June 1, 2020** | N/A | NIDDK is interested in studies to elucidate if COVID-19 might provoke or exacerbate noncommunicable gastrointestinal, liver, kidney/urological and metabolic/endocrine diseases in people with HIV or worsen the consequences of viral hepatitis coinfection. |
| Notice of Special Interest (NOSI) Regarding the Availability of Administrative Supplements for Research on COVID-19 [NOT-LM-20-010](https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-010.html) | **June 1, 2020** | N/A | NLM is encouraging the submission of applications for administrative supplements to active NLM R01 grants to address 1) methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, 2) public health surveillance methods that mine genomic, viromic, health data, environmental data and/or data from other pertinent sources |
| Pfizer: Providing Enhanced Medical Support for Patients with Primary Immunodeficiency (PI) Disorders ([linked here](https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020_IM-L-ManagementPIDisorders.pdf))  | **June 8, 2020** | Projects requesting up to $250,000 will be considered | To support patient-focused programs that help patients and providers address the heightened medical and educational needs of patients with primary immunodeficiency during this pandemic. Priority will be awarded to projects that use innovative technology platforms for distant learning to reach the intended audience with a focus on patient outreach, medical support and telework. *Found on the Office of Research Website*. |
| Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health [(Department of Defense; W81XWH-20-PRMRP-IIRA-COV)](https://www.grants.gov/web/grants/view-opportunity.html?oppId=326174) | **June 12, 2020** | A total program funding of $12,000,000 will be provided for approximately 4 awards | To support research with the potential to yield highly impactful data that could lead to critical discoveries or major advancements. |
| 23andMe Research Innovation Collaboration Program ([linked here](https://research.23andme.com/research-innovation-collaborations/)) | **June 12, 2020** | N/A | The 23andMe Research Innovation Collaborations Program works with academic researchers to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort. 23andMe will also consider proposals focused on COVID-19 that can include studies of outcomes, comorbidities, health disparities, and impacts of implemented policies. |
| Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01) ([RFA-HS-20-003](https://grants.nih.gov/grants/guide/rfa-files/RFA-HS-20-003.html)) | **June 15, 2020** | AHRQ expects to make up to $5 million available to fund awards in FY2020. The total costs will not exceed $500,000 in any given year and $1,000,000 for the entire project period. The project period may not exceed 2 years.  | To evaluate the responsiveness of healthcare delivery systems, healthcare profesionals, and the overall U.S. healthcare system to the COVID-19 pandemic. AHRQ is interested in evaluating topics such as effects on quality, safety, and value of health system response to COVID-19; the role of primary practices and professionals; understanding the effects on socially and medically vulnerable populations; and digital healthcare innovations and challenges. |
| Notice of Special Interest (NOSI): Data Driven Research on COVID-19 (R21) [NOT-LM-20-011](https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-011.html) | **June 16, 2020** | N/A | NLM is encouraging the submission of R21 applications to address the following research areas of interest 1) methods for mining clinical data that can be used to identify or predict COVID-19 presence in biomedical phenotype data, or other relevant topics, use of standard terminologies for these viruses in federated health data sets, 2) public health surveillance methods that mines genomic, viromic, health data, environmental data and/or data from sources including social media, to identify spread and impact of COVID-19 |
| Vaccine Preventable Diseases – COVID-19 ([linked here](https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-05/GMG_2020-VAC-G_VaccinePreventableDiseasesCOVID-19.pdf?yeKunKjIBisOfkWqBTSi7rf.quAjllQK&utm_source=Funding+Opportunities+Newsletter&utm_campaign=8c993175d3-EMAIL_CAMPAIGN_2020_04_14_08_58_COPY_01&utm_medium=email&utm_term=0_3c10bdadac-8c993175d3-199026908)) | **June 17, 2020;** Application reviews will be done on a rolling basis, and the intent is to review and make funding decisions on all applications within 10-14 days of submission.  | The expected range of grant awards is $50,000 to $250,000. Larger grants will be considered depending on the size and scope of the program. | Pfizer wants to support research to increase knowledge of COVID-19 epidemiology, infection, pathophysiology, and potential prevention measures. They are particularly interested in understanding the impact of COVID on communities, spectrum of disease in communities, and level of herd immunity, and postmortem analysis of decreased persons with known or suspected COVID-19.  |
| NOSI: Availability of Urgent Award for Competitive Revisions to IDeA-CTR Awards to Addres the Need for Documenting COVID-19-Related Patient Outcomes ([NOT-GM-20-033](https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-033.html)) | **June 18, 2020** | Application budgets are limited to no more than $500,000 in direct costs and one award is anticipated. | NIGMS will accept applications to active Idea-CTR U54 awards to rapidly provide supplemental funds to create a registry of COVID-19 patients across IDeA state sthat includes a comprehensive set of deidentified clinical data elements. |
| [MIT Solver Prize in Health Security and Pandemics](https://solve.mit.edu/challenges/health-security-pandemics) | **June 18, 2020** | Solve will award a $10,000 grant to each Solver selected during Solve Challenge Finals. [Additional amount may be provided](https://solve.mit.edu/challenges/health-security-pandemics/custom/prizes-1#challenge-subnav-offset).  | MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers. Solve is also seeking solutions that focus on preventative and mitigation measures that strengthen access to affordable primary healthcare systems, enhance disease surveillance systems, and improve healthcare supply chains. (This RFA was listed on the [Office of Research Development’s list](https://research.unc.edu/research-development/finding-funding/covid-19/)). |
| Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on SARS-CoV-2 and COVID-19 ([NOT-RM-20-015](https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-015.html)) | Applications will be accepted on a rolling basis through **June 19, 2020** | N/A | Purpose: In order to rapidly improve the understanding, diagnosis, and treatment of COVID-19, the Office of Strategic Coordination is encouraging the submission of innovative applications for Emergency Competitive Revisions to active Common Fund grants and cooperative agreements. Innovation may be technological or conceptual. Any relevant area of innovative research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. |
| Notice of Special Interest (NOSI): Administrative Supplements to Existing NIH Echo Cooperative Agreements (Admin Supp – Clinical Trial Not Allowed) for COVID-19 – Related Research [NOT-OD-20-107](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-107.html) | **June 22, 2020** | N/A | To encourage eligible ECHO cohort grantees to apply for this administrative supplement aimed at fostering time-sensitive ECHO-wide Cohort science related to the COVID-19 pandemic. Understanding the effects of a broad array of early environmental exposures on child health and development, including issues related to the COVID-19 pandemic, is a priority for the NIH. |
| NOSI: NCI Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on COVID-19 [(NOT-CA-20-042)](https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-042.html) | Applications will be accepted on a rolling basis through **June 25, 2020** | N/A | Topics of special interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infect3d persons in the context of cancer.  |
| Department of Veterans Affairs Supplemental Funding Opportunity for Research Related to COVID-19 **(**[**linked here**](https://www.research.va.gov/services/csrd/CSRD-COVID19-Research-Supplement-Request.pdf)**)** | CSRD will accept applications at any time up to **July 1, 2020**. | The budget may be up to 9 months for a minimum of $25,000.  | Clinical Science Research and Development Service is announcing this FOA for eligible VA investigators to request support for efforts related to better understanding, preventing, diagnosing, and treating COVID-19. This supplement may take the form of smaller short-term pilot projects or planning efforts that are intended to support research, build collaborative partnerships, develop capacity, and conducting the foundational work necessary to support larger studies.  |
| Investigator Studies Program (MISP): SARS-CoV-2/COVID-19 ([linked here](http://engagezone.msd.com/SARS_Cov-2_COVID-19.php)) | **July 24, 2020** | N/A | The Investigator Studies Program Review Committee (MISP-RC) will accept proposals within areas of SARS CoV02 /COVID1-19. The committee is looking for proposals related to virology/immunology, host immunology, primary epidemiology, secondary impacts in persons with COVID-19, and proposals looking at the public’s confidence of a vaccine. |
| Strengthening Access to Care for Opioid Use Disorder Patients During the COVID-19 National Public Health Emergency: Recovery Support Services ([linked here](https://forefdn.org/wp-content/uploads/2020/05/COVID19_RFP_FINAL_5-22-2020.pdf)) | A required short structured concept note is due **July 31, 2020**. Invited applicants will have two weeks from notification to submit the full proposal.  | Applicants may apply for a small grant of up to $25,000 or a larger grant of up to $75,000. Grant timelines are for up to one year. | The Foundation for Opioid Response Efforts will support specific projects that aim to strengthened access to evidence-based OUD recovery services for vulnerable and high-risk populations, and which can provide recovery support services in the context of social distancing and infection control, including promotion of remote, digital, and virtual forms of recovery support to reach vulnerable and broader populations. |
| Gilead COVID-19 Unmet Medical Needs and Associated Research Extension ([linked here](https://www.gilead.com/science-and-medicine/research/investigator-sponsored-research/covid19-commit-rfp)) | Letter of Intent is due on **August 3, 2020.** Top ranked LOIs will be invited to submit a full application. | Budgets should be no more than $250,000. Projects that are more than $250,000 will require approval by Gilead prior to submission. | This program will support individual projects that has relevance to the medical community. Gilead will consider support for research proposals that meet one of the following criteria: 1) expand data on clinical course and outcome in vulnerable populations, 2) look at long-term sequelae, 3) examine real world safety and effectiveness of remdesivir used alone or with other agents. |
| Superfund Research Program Occupational Health and Safety Education Programs on Emerging Technologies (R25-Clinical Trial Not Allowed) [RFA-ES-20-011](https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-011.html) | **August 3, 2020** | The Superfund Research Program intends to commit approximately $1,500,000 in FY21 to support around 4-6 awards. The total project period may not exceed 5 years. | To provide an opportunity to institutions of higher education to develop and offer continuing education courses, research experiences, and academic curricula on occupational health and safety management and laboratory practices in the areas of emerging technologies, emerging contaminants, and/or disaster response. |
| Robert Wood Johnson Foundation Systems for Action: Supplemental Research on COVID-19 Response and Recovery ([linked here](https://www.rwjf.org/en/library/funding-opportunities/2020/systems-for-action-supplemental-research-on-covid19-response-and-recovery.html)) | **August 5, 2020** (LOI is due July 20, 2020 – not required but highly encouraged) | RWJF will fund up to $100,000 / year. Studies should be completed in 1-2 years. Up to five awards will be funded. | This RFP will provide supplemental research funding to teams that are already engaged in the study of a promising system alignment mechanism, with the objective of learning how this mechanism performs in addressing health and social needs during the COVID-19 pandemic.  |
| Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional) [RFA-OD-20-013](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-013.html) | **August 7, 2020** | NIH intends to commit $7.5 Million in FY2020 to fund one award. The total project period may not exceed 4 years. | ***This is a Limited Submission opportunity that allows only one application per institution. The Office of Research Development will most likely be coordinating this.***This FOA provides an expedited funding mechanism as part of the RADx-UP initiative, a consortium of community-engaged research projects to understand factors that have led to disproportional burden of the pandemic on the underserved and/or vulnerable populations. This FOA seeks to fund a single Coordination and Data Collection Center as an integral part of the consortium. |
| Genentech 2020 Health Equity Innovations Fund ([linked here](https://www.gene.com/assets/frontend/pdf/content/good/grants/2020_Health_Equity_Innovations_Fund_CGN.pdf)) | Letters of intent are due **August 10, 2020**. Notification of LOI Acceptance / Denial will be September 8, 2020. | Grant awards will range from $250,000 to $750,000 | To support groundbreaking efforts to address healthcare disparities for historically underserved communities, with a focus on communities of color. |
| North Carolina Biotechnology Center Flash Grants ([linked here](https://www.ncbiotech.org/flash-grant)) | **August 12, 2020 – noon.** | The maximum award amount is $20,000. | The program aims to identify and energize the most creative ideas that exhibit early indications of commercial potential. The first cycle of flash grants are looking for projects addressing COVID-19 specific therapies, vaccine development, diagnosis, and epidemiology. (This cycle is also looking for novel antibiotics and therapeutics targeting antibiotic-resistant bacteria).  |
| Notice of Special Interest (NOSI): NCI Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during COVID-19 ([NOT-CA-20-082](https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-082.html)) | Applications will be accepted on a rolling basis **through August 14, 2020**. | N/A | NCI is announcing an opportunity for current NCI funded PIs whose postdoctoral fellows have temporarily lost stipend support from a non-profit funder because of the COVID-19 global pandemic to apply for an administrative supplement to over the postdoctoral fellow’s salary plus applicable F&A for the time and effort devoted to the NCI funded grant. |
| Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on SARS-CoV-2 and COVID-19 [NOT-AT-20-012](https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-012.html) | Accepted on a rolling basis through **August 17, 2020.** | N/A | Funds are now available to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on SARS-CoV-2 and COVID-19. NCCIH is particularly interested in projects focusing on the therapeutic and/or mechanistic effects of natural product-based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations. |
| Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) [PAR-20-256](https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html) | Applications will be accepted on a rolling basis beginning July 13, 2020. | NIAID intends to commit up to $25M for this initiative, and awards are made for one year only. | To provide PPE to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19 to ensue that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with patients. *Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.*  |
| Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Wastewater Surveillance Research for Public Health Response to COVID-19 ([NOT-OD-20-159](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-159.html)) | Applications will be accepted immediately through **August 21, 2020** | N/A | NIH is seeking applications from current NLM R01 awardees that can, in one or two years, enhance public health infrastructure for predicting and monitoring viral disease outbreaks.  |
| Open Innovation 2020 Research Grants – Pandemic Preparedness / Fighting Emerging New Viral Infectious Disease ([linked here](https://www.emdgroup.com/en/research/open-innovation/2020-research-grants/research-grant-pandemic-preparedness.html)) | Applications will be accepted through **August 31, 2020**. | €100,000 to €500,000 will be provided per year for up to three (3) years  | ***Please contact Joonhyung Cho (******Joonhyung.cho@unc.edu******), Director of Business Development, Industry Relations, if you are interested in applying. He can provide more information and assistance.***EMD Serono (Merck KGaA, Darmdstadt, Germany) is accepting first phase applications to support proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections. Sub-areas of focus include pre-outbreak R&D Preparedness for pandemic disease and response during outbreak |
| Encephalitis and COVID-19 Seed Funding ([linked here](https://www.encephalitis.info/seedfund)**)** | **August 31, 2020** | Researchers can apply for up to **£10,000** | The Encephalitis Society is inviting applications for seed funding for a project on encephalitis and COVID-19 with a duration of up to 18 months. The organizations wants to hear from anyone who wants to develop compelling and innovative ideas which look at anything from diagnosis and treatment, through to recovery and rehabilitation. |
| Research Grant for Pandemic Preparedness ([Merck KGaA- proposed linked here](https://www.emdgroup.com/en/research/open-innovation/2020-research-grants/research-grant-pandemic-preparedness.html)) | **August 31, 2020** (for the pandemic preparedness topic, there is no fixed deadline) | Merck KGaA is offering a grant comprising up to 500,000 €/year for 3 years with the option of extension | For technical solutions towards pandemic outbreak preparedness or solutions that could help fighting emerging viral infections. Grants are available in the areas of drug discovery, bioreactor design for cultured meat, next generation machine learning, pandemic preparedness / fighting new emerging viral infectious diseases(This RFA was listed on the [Office of Research Development’s list](https://research.unc.edu/research-development/finding-funding/covid-19/), therefore I am assuming we are eligible). |
| NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required) [PAR-20-234](https://grants.nih.gov/grants/guide/pa-files/PAR-20-234.html?utm_source=Master%3A+Research+Rundown+%2F+Funding&utm_campaign=387a884f40-EMAIL_CAMPAIGN_2020_04_14_08_58_COPY_02&utm_medium=email&utm_term=0_9d8dbeb58a-387a884f40-206301660) | **September 1, 2020**, October 1, 2020; November 2, 2020; December 1, 2020; January 2, 2021; February 1, 2021 | N/A | This FOA invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of COVID-19. *Please see the RFA for a list of the priority topics*. |
| March of Dimes RFA for 2020 COVID-19 Fund ([linked here](https://www.marchofdimes.org/research/request-for-applications-2020-covid-19-fund.aspx)) | **September 4, 2020** | Proposals should have a budget range of $100,000 - $125,000.  | The March of Dimes COVID-19 is seeking applications proposing research in one of the following areas:* Clinical characteristics – examines clinical and sociodemographic predictors of perinatal health outcomes and treatments with COVID-19 for the mom-baby dyad.
* Maternal Immunity and Neonatal Health – includes studies examining the role of antibody testing in birth planning and postpartum care, sustainability of antibodies, viability of passive immunity, and mom-to-baby contact
 |
| NIH Director’s Emergency Early Independence Awards (DP5 Clinical Trial Optional) [RFA-RM-20-021](https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-021.html) | **September 4, 2020** | The awards will be for up to $250,000 in direct costs per year plus applicable F&A costs. The project period is limited to 5 years. | *This is a Limited Submission Opportunity being coordinated by the Office of Research Development*This award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training. Due to the COVID-19 emergency, the Common Fund will dedicate funds to 5-10 early independence awards that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. |
| Notice of Special Interest: Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations [NOT-OD-20-119](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-119.html) | Applications may be submitted beginning July 8, 2020 for Application Due Dates of August 7, 2020 OR **September 8, 2020**. | N/A | The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. The Office of the Director is therefore offering Emergency Competitive Revisions to active eligible grants and cooperative agreements addressing the objectives better described in the notice. |
| Notice of Special Interest: Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations [NOT-OD-20-120](http://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-120.html) | Applications may be submitted beginning July 8, 2020 for Application Due Dates of August 7, 2020 OR **September 8, 2020**. | N/A | To support two-year community-engaged Testing Research Projects that will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the RADx-UP initiative.  |
| Notice of Special Interest (NOSI): Select Research Areas for SARS-CoV-2 and COVID-19 ([NOT-AI-20-051](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-051.html))  | This notice expires on **September 8, 2020** | N/A | Using the NIH Small Research Grant Program (R03), the Parent SBIR [R43/R44] and Parent STTR mechanisms, NIAID is issuing this NOSI to address a number of interest areas including studies to understand the aspects of viral infection, replication, pathogenesis and transmission, factors that affect viral host-range and virulence, development of rapid diagnostics and therapeutic candidates, and the development of SARS-CoV-2 vaccine candidates. |
| Junior Faculty Research Grants for the Study of Lung Cancer and COVID-19 Infection ([linked here](https://laaresearchgrants.secure-platform.com/a/page/Guidelines)) | **September 15, 2020** | The minimum funding for the award will be $50,000. | The Lung Ambition Alliance will fund groundbreaking research related to COVID-19 infected lung cancer patients, and to provide junior faculty researchers to obtain preliminary data to compete for national peer-reviewed grant support |
| Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed) ([RFA-OD-20-014](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-014.html)) | **September 15, 2020** | NIH intends to fund an estimate of 10 awards corresponding to about $10M for FY2020 and 2021. The maximum project period is 2 years. | This RFA will support early-stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. |
| Emergency Awards: RADx-rad Wastewater Detection of SARS-CoV-2 (COVID-19) (U01 Clinical Trials Not Allowed) [RFA-OD-20-015](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-015.html) | **September 15, 2020** | NIH intends to commit $19 Million to fund 5-10 awards. The maximum project period is 2 years. | This FOA will support wastewater-based testing surveillance which can provide detailed mapping of the extent and spread of COVID-19. |
| Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool ([NOT-OD-20-152](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-152.html))  | **September 15, 2020** | N/A | The goal of this NOSI is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. |
| Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional) [RFA-OD-20-022](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-022.html#_3._Additional_Information) | **September 15, 2020** | NIH intends to commit approximately $7M in the FY2021 to fund 5-6 awards. The maximum project period is 3 years.  | To solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. |
| Emergency Awards: RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed) [RFA-OD-20-017](http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-017.html) | **September 18, 2020** | NIH intends to commit $10 million in total costs over a 2-year period for 5 awards. The maximum project period is 2 years. | ***This is a Limited Submission Opportunity that will likely be coordinated by the Office of Research Development. Also see Companion Funding Opportunities in RFA***This FOA is seeking applications for a portable sensing device to detect volatile organic compounds emanating from skin or exhaled breadth, saliva and different oral tissues from the oral cavity. |
| Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed) [RFA-OD-20-018](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-018.html) | **September 18, 2020** | NIH intends to commit $10 million total costs over a 2 year period. NIH anticipates funding 5 awards. The maximum project period is 2 years. | ***This is a Limited Submission Opportunity that will likely be coordinated by the Office of Research Development. Also see Companion Funding Opportunities in RFA***This FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. |
| PCORI’s Response to COVID-19: Phased Large Awards for Comparative Effectiveness Research – Cycle 3 2020 ([linked here](https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-cycle-3-2020?utm_source=weeklyemail&utm_medium=email&utm_campaign=060920)) | Letters of intent are due by **Tuesday, September 29, 2020**. Full applications will be due Tuesday January 12, 2021. |  | This PCORI FOA invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and stakeholders. Investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs.  |
| Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAILkIds) (R61/R33 Clinical Trial Optional) [RFA-OD-20-023](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-023.html#_3._Additional_Information) | **September 30, 2020** | NIH OD intends to commit $5M in FY2021 to fund approximately 5-6 awards. The maximum project period for an application cannot exceed 4 years.  | To support innovative research to develop novel, new or unique and non-traditional approaches to identify and characterize the spectrum of SARS-CoV-2associated illness, including the multisystem inflammatory syndrome in children and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to tailor management and optimize health outcomes. |
| Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) [RFA-OD-20-016](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html) | **September 30, 2020** | NIH intends to commit $7M in FY2021 to fund 6-8 awards. The total project period may not exceed 3 years. | This FOA seeks applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions with a high density of individuals who are together for prolonged periods of time. |
| Medical Robotics for Contagious Diseases Challenge 2020 ([linked here](https://www.ukras.org/robotics-week/challenges/medical-robotics-for-contagious-diseases-challenge-2020/)) | **September 30, 2020** | The prize fund amount is £15,000 | Robotics has a key role to play in the COVID-19 pandemic and have been deployed as part of the response. In the case of clinical care, areas of specific importance include disease prevention, diagnosis and screening, and patient care and disease management. A 2-minute video demo is required as part of the entry. |
| COVID-19 Small Grants Program ([ND-NOFO-20-111](https://www.grants.gov/web/grants/view-opportunity.html?oppId=326595))  | **September 30, 2020** | The award ceiling is $100,000 | This FOA from the Department of State seeks to support coalitions that will bolster and leverage U.S. – India collaboration across a range of fields to fight COVID-19 in India and globally. Projects may include, but are not limited to, support accurate public messaging, build capacity of local NGOs to engage communities in virtual/online conversations, organize capacity-building initiatives to maintain strong operations, and other project ideas that promote U.S. – India cooperation in combating COVID-19 |
| NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional) [RFA-RM-20-020](https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html) | **September 30, 2020** | Application budgets are not limited but must be commensurate with the scope of the proposed research. The maximum project period is 5 years.  | The Common Fund will support 5-10 transformative research awards that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. |
| COVID-19 Small Grants Program Department of State U.S. Mission to India ([ND-NOFO-20-111](https://www.grants.gov/web/grants/view-opportunity.html?oppId=326595)) | **September 30, 2020** | The award ceiling is $100,000 | To support effective coalitions that will bolter and leverage U.S.-India collaboration across a range of fields to fight COVID-19, in India and globally. Potential grantees should be able to implement a small-grants program to promote innovation in addressing COVID-19, encourage partnerships between U.S. and Indian Institutions and organization in combating COVID-19, and facilitate joint action that make a difference against the disease |
| Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on COVID-19 for Currently Active NHLBI Phase I-III Clinical Trials [NOT-HL-20-782](https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-782.html) | Applications will be accepted on a rolling basis **through October 5, 2020**. | N/A | NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19. Topics of specific interest to the NHLBI include the safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases.  |
| NOSI: Availability of Administrative Supplements and Urgent Competitive Revisions for research on Stress Management in Relation to COVID-19 [(NOT-AT-20-011)](https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-011.html) | Applications are accepted on a rolling basis through **October 6, 2020** | N/A | Topics of specific interest include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections. |
| Notice of Special Interest: Repurposing Existing Therapeutics to Address COVID-19 ([NOT-TR-20-012](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html)) | Applies to receipt date through **October 16, 2020**. See RFA for applicable dates | N/A | NCATS is issuing this NOSI to highlight the urgent need for SARS-CoV-2 and COVID-19 research. NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutic) that have already begun or completed a Phase I clinical trial. |
| Ignacio H. de Larramendi Research Grants ([linked here](https://www.fundacionmapfre.org/fundacion/en/grants-aids-and-awards/aids/ignacio-larramendi-research-grants/)) | **October 30, 2020** | Grants will total 240,000 euros.  | In the 2020 call, this mechanism will support research projects in the area of health promotion. Special attention will be given to projects that incorporate aspects related to COVID-19 such as reducing infections, self-care and the culture of self-protection, relationship between previous health status (lifestyle) and morbimortality, COVID-19 and mental health etc. |
| HHS Solicits Proposals for Development of Medical Products for Novel Coronavirus ([BAA-18-100-SOL-00003-Amendment 13](https://beta.sam.gov/opp/7c72ff2e5c514b2faa15765e78294128/view)) | **October 31, 2020** | Multiple awards of various values are anticipated and are dependent upon the program priorities and available funds. | To solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medications such as therapeutics or antivirals. |
| Ferring COVID-19 Investigational Grants ([linked here](http://www.ferring-research.com/ferring-grants/important-information/)) | Accepted through **October 31, 2020.** | The program will provide a limited number of research grants up to 25,000 Euro for each application. | Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects of SARS-CoV-2 on reproduction, pregnancy, and foetal/neonatal health. |
| Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for COVID-19 Research within the mission of NIDCR [NOT-DE-20-022](https://grants.nih.gov/grants/guide/notice-files/NOT-DE-20-022.html) | **November 2, 2020** | N/A | NIDCR will place a high priority on topics that would be of immediate and high impact to protect ad ensure the safety of personnel and patients in dental practices. These topics include prevention of SARS-COV-2 transmission and improvements in the detection and diagnosis of COVID-19; as well as acquisition of a more robust understanding of SARS-CoV-2 pathogenesis. Topics addressing influence and interaction of sex and gender, race and ethnicity, and those addressing questions about risk, prevention, and health outcomes are also of interest. |
| Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and UL24 CTSA awards to address COVID-19 Public Health Need [NOT-TR-20-029](https://grants.nih.gov/grants/guide/notice-files/not-tr-20-029.html?utm_source=Master%3A+Research+Rundown+%2F+Funding&utm_campaign=387a884f40-EMAIL_CAMPAIGN_2020_04_14_08_58_COPY_02&utm_medium=email&utm_term=0_9d8dbeb58a-387a884f40-206301660) | Applications will be accepted on a rolling basis **through November 10, 2020** | N/A | NCATS is soliciting applications for administrative supplements (through [PA-18-591](https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html)) from current Clinical and Translational Award (CTSA) UL1 and U24 award. *Please refer to the NOT for specific information about which FOAs this applies to*. |
| Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address COVID-19 Public Health Needs [NOT-TR-20-028](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-028.html) | Applications will be accepted on a **rolling basis through November 10, 2020**. | N/A | Purpose: NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current CTSA UL1 and U24 awards recipients. (Please see RFA for specific information).  |

***Funding Opportunities Relevant to the COVID-19 Pandemic***

*The opportunities listed below can apply to conditions related to COVID-19 Pandemic, such as supplements for difficult life-decisions or general pandemic-preparedness. If you are aware of RFAs that should be listed here, please email Trisha Dant at* *dant@med.unc.edu**. Those shaded in Gray have expired.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Title** | **Deadline** | **Funding Information** | **Purpose and Other Notes** |
| Notice of Special Interest: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars [NOT-OD-20-054](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-054.html) | [Refer to the Table of IC-Specific Information and Requirements](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-054.html) | N/A | The overarching goal is to support transition and retention of investigators from mentored career development to research independence and minimize departures from biomedical research workforce at critical junctures. The supplement may be used to support additional personnel, computational services, supplies, and equipment that will promote the continuity of the research project when the PD/PI experiences critical life events which can impact productivity.  |
| Notice of Special Interest (NOSI): Administrative Supplement for Continuity of biomedical and Behavioral research Among First-Time Recipients of NIH Research Project Grant Awards [NOT-OD-20-05](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-055.html)5 | [Refer to the Table of IC-Specific Information and Requirements](https://grants.nih.gov/grants/guide/contacts/NOT-OD-20-055.htm)  | N/A | To enhance the retention of investigators facing critical life events who are transitioning to the first renewal of their 1st independent research project grant award or to a second new NIH research project grant award by providing temporary supplemental research support to help sustain the investigator’s research during critical life events. PD/PIs of the following grants are eligible: DP1, DP2, DP5, R01, R00, R15, R21, R35, RF1, and U01. |
| Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01 – Clinical Trial Optional) [PA-20-172](https://grants.nih.gov/grants/guide/pa-files/PA-20-172.html) | **Standard Dates Apply**. The first due date for this FOA is October 5, 2020 | The maximum project period is 5 years | To support investigative and collaborative research focused on understanding the long-term effects of disasters on health care systems serving health disparity populations in communities in the U.S., including U.S. territories. Public health emergencies may include the COVID-19 pandemic. |